JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model

  • 0Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Therapeutic Advances in Medical Oncology +

|

May 13, 2024

|

May 13, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Residual breast cancer in lymph nodes after neoadjuvant chemotherapy (NAC) significantly lowers disease-free survival (DFS). A new nomogram predicts DFS, aiding personalized treatment for breast cancer patients.

Area Of Science

  • Oncology
  • Breast Cancer Research
  • Chemotherapy Efficacy

Background

  • Residual disease post-neoadjuvant chemotherapy (NAC) in breast cancer is linked to poorer outcomes.
  • The prognostic impact of residual tumor location (breast vs. lymph nodes) is not well understood.

Purpose Of The Study

  • To evaluate disease-free survival (DFS) based on residual tumor site after NAC.
  • To develop and validate a nomogram for predicting 1- to 3-year DFS in breast cancer patients with residual disease.

Main Methods

  • Retrospective analysis of 953 lymph node-positive breast cancer patients with residual disease post-NAC.
  • Patients classified into residual disease in breast (RDB), lymph nodes (RDN), or both (RDBN).
  • Developed a nomogram using training/validation sets, incorporating TNM stage, molecular subtype, and pathological response.

Main Results

  • Patients with residual disease only in the breast (RDB) showed significantly better 3-year DFS (94.6%) compared to those with lymph node involvement (RDN: 85.2%; RDBN: 81.8%).
  • Clinical T stage, N stage, molecular subtype, and postoperative pN stage were independent predictors of DFS.
  • The nomogram demonstrated good predictive performance (C-index 0.748 training, 0.796 validation).

Conclusions

  • The anatomical site of residual disease after NAC significantly impacts DFS, with lymph node involvement indicating a worse prognosis.
  • A validated nomogram can aid in personalized DFS prediction, guiding treatment decisions for breast cancer patients.

Keywords: